Recent advances in haematology

British Medical Journal

Volumn 318, Issue 7189, 1999, Pages 991-994

  Provan, Drew ^a   O'Shaughnessy, Denise F ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; BISPHOSPHONIC ACID DERIVATIVE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 9; CLADRIBINE; COMPLEMENTARY DNA; DNA VACCINE; FLUDARABINE; FOLIC ACID ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RIBOZYME; TRANSFERRIN RECEPTOR;

DNA PROBE; GENE MUTATION; HEMATOLOGIC DISEASE; HEMATOLOGY; HEMOPHILIA; HERPES VIRUS; HUMAN; HYPERHOMOCYSTEINEMIA; IRON DEFICIENCY ANEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SHORT SURVEY; THROMBOSIS;

EID: 0033541617     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.318.7189.991     Document Type: Short Survey

References (29)

1. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia in chronic disease. Blood 1992;80:1639-47.
2. Baer AN, Dessypris EN, Krantz SB. The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis. Semin Arthritis Rheum 1990;19:200-23.
3. Seligman PA, Schleicher RB, Allen RH. Isolation and characterization of the transferrin receptor from human placenta. J Biol Chem 1979;254:9943-6.
4. Kohgo Y, Niitsu Y, Nishisato T, Kato J, Kondo H, Sasaki K, et al. Quantitation and characterization of serum transferrin receptor in patients with anemias and polycythemias. Jpn J Med 1988;27:64-70.
5. Roberts HR, Ebest ME. Current management of hemophilia B. Hematol Oncol Clin North Am 1993;7:1269-80.
6. Berntorp E. Second generation B-domain deleted recombinant factor VIII. Thromb Haemost 1997;78:256-60.
7. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997;78:261-5.
8. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
9. Dahlback B, Carlsson M, Stevenson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-8.
10. Takiyama O, Ishida F, Kodaira H, Kitano K. APC-resistance and MnH genotype (Gln506) of coagulation factor V are rare in Japanese population. Thromb Haemost 1995;74:996.
11. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
12. 300Thr) associated with resistance to activated protein C. Blood 1998;91:1140-4.
13. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbrouke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993;342:1503-6.
14. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
15. Poort SR, Michiels JJ, Reitsma PH, Bertina RM. Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder. Thromb Haemost 1994;72:819-24.
16. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increased incidence of venous thrombosis. Blood 1996;88:3698-703.
17. McCully KS. Vascular pathology of homocysteinemia. Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
18. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90:1-11.
19. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
20. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995;162:248-55.
21. Bataille R, Harousseau J-L. Multiple myeloma. N Engl J Med 1997;336:1657-64.
22. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712-20.
23. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposis sarcoma. Science 1994;266:1865-9.
24. Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997;276:1851-1.
25. Chee M, Yang R, Hubbel E, Berno A, Huang XC, Stern D, et al. Accessing genetic diversity with high density DNA arrays. Science 1996;274: 610-14.
26. Bayever E, Iversen PL, Bishop MR, Sharp JG, Tewary HK, Arneson MA, et al. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelody splastic syndrome: initial results of a phase I trial. Antisense Res Devel 1993;3:383-90.
27. De Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Belluci R, et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 1998;91:156-62.
28. Schrump DS, Chen A, Consoli U. Inhibition of lung cancer proliferation by antisensory cyclin. D. Cancer Gene Ther 1996;3:131-5.
29. Irie A, Kijima H, Ohkawa T, Bouffard DY, Suzuki T, Curcio LD, et al. Antioncogne ribozymes for cancer gene therapy. Adv Pharmacol 1997;40:207-57.